全文获取类型
收费全文 | 2587268篇 |
免费 | 185056篇 |
国内免费 | 7569篇 |
专业分类
耳鼻咽喉 | 34272篇 |
儿科学 | 85196篇 |
妇产科学 | 71568篇 |
基础医学 | 363571篇 |
口腔科学 | 69659篇 |
临床医学 | 234493篇 |
内科学 | 515479篇 |
皮肤病学 | 62451篇 |
神经病学 | 213440篇 |
特种医学 | 99879篇 |
外国民族医学 | 736篇 |
外科学 | 386407篇 |
综合类 | 50391篇 |
现状与发展 | 5篇 |
一般理论 | 968篇 |
预防医学 | 196163篇 |
眼科学 | 56663篇 |
药学 | 187992篇 |
8篇 | |
中国医学 | 5331篇 |
肿瘤学 | 145221篇 |
出版年
2021年 | 19980篇 |
2019年 | 20619篇 |
2018年 | 29283篇 |
2017年 | 22591篇 |
2016年 | 26223篇 |
2015年 | 29500篇 |
2014年 | 40437篇 |
2013年 | 60420篇 |
2012年 | 80217篇 |
2011年 | 84478篇 |
2010年 | 50998篇 |
2009年 | 49142篇 |
2008年 | 79017篇 |
2007年 | 83828篇 |
2006年 | 85560篇 |
2005年 | 81723篇 |
2004年 | 78719篇 |
2003年 | 76037篇 |
2002年 | 73326篇 |
2001年 | 128406篇 |
2000年 | 131330篇 |
1999年 | 110499篇 |
1998年 | 31253篇 |
1997年 | 27919篇 |
1996年 | 28217篇 |
1995年 | 27383篇 |
1994年 | 25067篇 |
1993年 | 23420篇 |
1992年 | 85161篇 |
1991年 | 81563篇 |
1990年 | 78784篇 |
1989年 | 76059篇 |
1988年 | 69469篇 |
1987年 | 67996篇 |
1986年 | 63542篇 |
1985年 | 60510篇 |
1984年 | 44940篇 |
1983年 | 37945篇 |
1982年 | 22457篇 |
1981年 | 19985篇 |
1979年 | 38959篇 |
1978年 | 27439篇 |
1977年 | 23252篇 |
1976年 | 21495篇 |
1975年 | 22813篇 |
1974年 | 26786篇 |
1973年 | 25370篇 |
1972年 | 23749篇 |
1971年 | 21955篇 |
1970年 | 20184篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
63.
64.
P E Santos E Piontelli Y R Shea M L Galluzzo S M Holland M E Zelazko S D Rosenzweig 《Medical mycology》2006,44(8):749-753
Infections due to Penicillium species other than P.marneffei are rare. We identified a boy with X-linked chronic granulomatous disease (X-CGD) with a pulmonary nodule and adjacent rib osteomyelitis caused by Penicillium piceum. The only sign of infection was an elevated sedimentation rate. P. piceum was isolated by fine needle aspirate and from excised infected tissues. Surgical removal and one year of voriconazole treatment were very well tolerated and led to complete recovery. Microbiological, microscopic and molecular studies support the fungal diagnosis. P. piceum should be considered as a relevant pathogen in immunocompromised patients. 相似文献
65.
66.
ABSTRACT: Background: Although increases in perinatal mortality risk associated with fetal macrosomia are well documented, the optimal route of delivery for fetuses with suspected macrosomia remains controversial. The objective of this investigation was to assess the risk of neonatal death among macrosomic infants delivered vaginally compared with those delivered by cesarean section. Methods: Data were derived from the U.S. 1995–1999 Linked Live Birth‐Infant Death Cohort files and term (37–44 wk), single live births to United States resident mothers selected. A proportional hazards model was used to analyze the risk of neonatal death associated with cesarean delivery among 3 categories of macrosomic infants (infants weighing 4,000–4,499 g; 4,500–4,999 g; and 5,000+ g). Results: After controlling for maternal characteristics and complications, the adjusted hazard ratio for neonatal death associated with cesarean delivery among the 3 categories of macrosomic infants was 1.40, 1.30, and 0.85. Conclusions: Although cesarean delivery may reduce the risk of death for the heaviest infants (5,000+ g), the relative benefit of this intervention for macrosomic infants weighing 4,000–4,999 g remains debatable. Thus, policies in support of prophylactic cesarean delivery for suspected fetal macrosomia may need to be reevaluated. (BIRTH 33:4 December 2006) 相似文献
67.
68.
Marlene L Hauck Susan M LaRue William P Petros Jean M Poulson Daohai Yu Ivan Spasojevic Amy F Pruitt Allison Klein Beth Case Donald E Thrall David Needham Mark W Dewhirst 《Clinical cancer research》2006,12(13):4004-4010
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted. 相似文献
69.
70.